Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In ...

No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Rosalie Chan Every time Rosalie publishes a story, you’ll get an alert straight to your inbox!

) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...